Skip to main content
Erschienen in: World Journal of Urology 9/2018

02.05.2018 | Original Article

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer

verfasst von: Marco Bandini, Michele Marchioni, Felix Preisser, Emanuele Zaffuto, Zhe Tian, Derya Tilki, Francesco Montorsi, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Pierre I. Karakiewicz

Erschienen in: World Journal of Urology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa.

Methods

Within the SEER database (2004–2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses.

Results

Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP.

Conclusions

CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
10.
Zurück zum Zitat National cancer institute surveillance, epidemiology, and end results prostate-specific antigen working group, Adamo MP, Boten JA et al (2017) Validation of prostate-specific antigen laboratory values recorded in surveillance, epidemiology, and end results registries. Cancer 123:697–703. https://doi.org/10.1002/cncr.30401 CrossRef National cancer institute surveillance, epidemiology, and end results prostate-specific antigen working group, Adamo MP, Boten JA et al (2017) Validation of prostate-specific antigen laboratory values recorded in surveillance, epidemiology, and end results registries. Cancer 123:697–703. https://​doi.​org/​10.​1002/​cncr.​30401 CrossRef
23.
24.
Zurück zum Zitat Akakura K, Suzuki H, Ichikawa T et al (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36:789–793. https://doi.org/10.1093/jjco/hyl115 CrossRefPubMed Akakura K, Suzuki H, Ichikawa T et al (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36:789–793. https://​doi.​org/​10.​1093/​jjco/​hyl115 CrossRefPubMed
Metadaten
Titel
Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer
verfasst von
Marco Bandini
Michele Marchioni
Felix Preisser
Emanuele Zaffuto
Zhe Tian
Derya Tilki
Francesco Montorsi
Shahrokh F. Shariat
Fred Saad
Alberto Briganti
Pierre I. Karakiewicz
Publikationsdatum
02.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 9/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2310-y

Weitere Artikel der Ausgabe 9/2018

World Journal of Urology 9/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.